| Overview |
| bs-9910R-HRP |
| GPLD1 Polyclonal Antibody, HRP Conjugated |
| WB, IHC-P |
| Human, Mouse, Rat |
| Specifications |
| HRP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GPLD1/GPI-PLD |
| 51-150/840 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 2822 |
| Glycoprotein phospholipase D; Glycosyl-phosphatidylinositol-specic phospholipase D; GPI-PLD; GPI-specic phospholipase D; GPIPLD; GPIPLDM; GPLD1; PHLD_HUMAN; Phosphatidylinositol glycan specic phospholipase D; Phosphatidylinositol-glycan-specic phospholipase D; PI-G PLD; PIGPLD; PIGPLD1. |
| Phosphatidylinositol-glycan-specific phospholipase D (GPI-PLD) is a high-density lipoprotein-associated protein found on chromosome 6p22 that specifically hydrolyzes the inositol phosphate linkage in proteins anchored by phosphatidylinositol-glycans (PI-Gs). GPI-PLD is found in serum, liver, cerebrospinal fluid and in milk. The majority of plasma GPI-PLD appears to be specifically associated with a small, discrete and minor fraction of lipoproteins containing apoA-I and apoA-IV. Serum GPI-PLD activity is reduced over 75% in systemic inflammatory response syndrome and the downregulation of GPI-PLD could play an important role in the control of proinflammatory responses. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
Powered by Bioz